Literature DB >> 19481016

Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease.

Brian R Stephany1, Mirna Boumitri, Marie Budev, Bashar Alao, Emilio D Poggio.   

Abstract

BACKGROUND: Improvement in renal function has been noted in some lung allograft recipients with chronic kidney disease (CKD) converted from a calcineurin inhibitor (CNI)- to a sirolimus (SRL)-based immunosuppressive regimen. However, not all patients have such a positive response. We sought to investigate independent predictors of a favorable renal response in a cohort of lung transplant recipients.
METHODS: We retrospectively studied 56 lung transplant recipients with CKD, defined as a pre-conversion estimated glomerular filtration rate (eGFR) < or =60 ml/min/1.73 m(2), who had been converted to CNI-sparing regimens using SRL (CNI-free: n = 10; CNI dose reduction + SRL: n = 46). Proteinuria prior to conversion, defined as > or =1(+) on urine dipstick, was determined when available (n = 51). Changes in mean eGFR post-conversion and independent predictors of a favorable renal response, defined as a rise in eGFR > or =20% within 1 month, were investigated.
RESULTS: Mean eGFR at conversion was 35 +/- 14 ml/min/1.73 m(2), increasing by 8 +/- 14 ml/min/1.73 m(2) (p < 0.01) by 1 month post-conversion, a trend that remained significant out to 18 months. A total of 43% (n = 24) of patients had a rise in eGFR > or =20%. Forced expiratory volume in 1 second (FEV(1)) remained stable in survivors maintained on SRL and only 1 rejection episode occurred. When controlling for gender, age, pre-conversion eGFR and CNI-free vs CNI-dose reduction, the only variable that remained independently predictive of a favorable renal response was absence of proteinuria, with an odds ratio = 3.3 (95% confidence interval 1.0 to 12.5, p = 0.05).
CONCLUSIONS: Non-proteinuric lung transplant survivors with CKD are more likely to respond favorably from a renal standpoint after conversion to SRL with CNI-dose reduction or elimination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19481016     DOI: 10.1016/j.healun.2009.03.010

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  5 in total

Review 1.  The Evolution of Lung Transplant Immunosuppression.

Authors:  Steven Ivulich; Glen Westall; Michael Dooley; Gregory Snell
Journal:  Drugs       Date:  2018-07       Impact factor: 9.546

Review 2.  Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.

Authors:  Vicente E Torres; Alessandra Boletta; Arlene Chapman; Vincent Gattone; York Pei; Qi Qian; Darren P Wallace; Thomas Weimbs; Rudolf P Wüthrich
Journal:  Clin J Am Soc Nephrol       Date:  2010-05-24       Impact factor: 8.237

3.  The Effect of Monthly Anti-CD25+ Treatment with Basiliximab on the Progression of Chronic Renal Dysfunction after Lung Transplantation.

Authors:  D J Ross; J Belperio; C Natori; A Ardehali
Journal:  Int J Organ Transplant Med       Date:  2020

4.  Cardiorenal benefits of early versus late cyclosporine to sirolimus conversion in a rat model.

Authors:  José Sereno; Ana M Romão; Belmiro Parada; Patrícia Lopes; Eugénia Carvalho; Frederico Teixeira; Flávio Reis
Journal:  J Pharmacol Pharmacother       Date:  2012-04

Review 5.  Kidney disease in non-kidney solid organ transplantation.

Authors:  Kurtis J Swanson
Journal:  World J Transplant       Date:  2022-08-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.